PeptideStack
5.2kquestions
20kanswers
220users

How many freeze-thaw cycles will oral semaglutide at 4 mg/mL tolerate?

Asked 7 Jul 2024Modified 22 months agoViewed 29k times
17

The particulars: oral semaglutide · 4 mg/mL.

I have read the obvious sources and they disagree with each other, so I would rather ask people who have actually done this.

I have a working setup and a notebook, and I am prepared to be told that my setup is inadequate if that is the answer.

Which parts of this are load-bearing and which parts are habit?

freeze-thaw
freeze-thaw

What repeated freezing does to a peptide in solution: ice-crystal shear at the growing front, freeze-concentration of solutes, pH shifts as buffer…

57 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
shareeditfollowflag
SW
askedswab_and_wait13k167 Jul 2024

5 Answers

Sorted by votes
85

Nobody has published a cycle count, and at 4 mg/mL the concentration tells you what a wrong guess costs: a 0.1 mL aliquot holds 0.4 mg and every microlitre is 4 µg. Damage from freezing is not gradual attrition — it is concentrated at the phase transitions, where ice excludes solute and the unfrozen fraction climbs well above 4 mg/mL for as long as the transition lasts. Two slow cycles can therefore do more than four fast ones, which is why a cycle count is the wrong unit in the first place. The way to make the number one is to make it one: split at reconstitution into single-draw aliquots, label each with 4 mg/mL and the date, and never thaw a container you will refreeze.

The short version: aliquot before freezing, thaw slowly, never refreeze a thawed aliquot, and count your cycles.

Never refreeze a thawed aliquot. The whole point of aliquoting is that the aliquot is single-use, and refreezing it discards the benefit.

More usefully, the mitigation is aliquoting. Divide the reconstituted solution into single-use volumes before the first freeze, and each aliquot then experiences exactly one cycle.

Cryoconcentration of solutes at the ice front is a well-documented mechanism in freeze-thaw damage to proteins and peptides.

Thaw slowly and never refreeze an aliquot.

edited 8 Oct 2024 by lyoph_cake — reworded for clarity after a comment

shareimprove this answerflag
LC
answeredlyoph_cake78k26710 Sept 2024
The desiccant point is under-appreciated and costs nothing to act on. – h_villanueva 4 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
58

Buffer components crystallise at different rates during freezing, which shifts pH locally by a surprising amount.

Let a frozen vial reach room temperature before opening it. Opening a cold vial in humid air condenses water into the cake, which raises residual moisture and undoes what lyophilisation achieved.

Count cycles rather than worrying about degrees. Minus twenty and minus eighty differ far less than one cycle and five do.

Aliquoting to eliminate repeated cycles is standard laboratory practice for exactly this reason.

Dry powder tolerates cycles far better than solution does.

shareimprove this answerflag
FC
answeredforty_two_c66k5830 Aug 2024
41

The relevant physics is ice-front concentration: as water crystallises, everything dissolved is concentrated into the shrinking liquid phase, including buffer salts.

During freezing, solutes are excluded from the ice lattice and concentrate into the residual liquid. Local concentrations can rise many-fold, which promotes aggregation independently of temperature.

A dry lyophilised powder is much less affected by a temperature cycle because there is no liquid phase for anything to concentrate into. Condensation on a cold vial opened warm is the real risk there.

Aliquot before the first freeze. That is the whole answer.

shareimprove this answerflag
WO
answeredw_okoye43k13719 Aug 2024
34

In practice, thawing at room temperature rather than in warm water reduces the interfacial stress.

Buffer salts crystallise at different points during freezing. Sodium phosphate is the classic example: the dibasic form crystallises first and the pH of the residual liquid falls by several units. That pH excursion is the real damage in many cases.

Condensation onto cold lyophilised material on opening is a recognised handling error and is the basis for the equilibrate-before-opening rule.

The caveat is that aggregation is invisible in a clear solution below the threshold where it becomes visible.

Count cycles, not degrees. The cycle is the damaging event.

shareimprove this answerflag
AP
answeredarea_percent9.9k168 Aug 2024
4Does the same reasoning apply to material already in solution, or is that a different curve? – a_lindgren 10 months ago
3Adding for future readers: the domestic leg after delivery is the part you control. – RP_C18 8 months ago
add a comment
31

Answer first: each freeze-thaw cycle costs something through aggregation and pH shift, so the mitigation is aliquoting rather than choosing a better freezer.

Thaw slowly at room temperature or in the refrigerator rather than in warm water. Rapid warming creates local thermal and concentration gradients that promote aggregation.

Aliquoting itself is a handling step and introduces its own contamination opportunity.

Let a frozen vial reach room temperature before opening, or you condense water into it.

shareimprove this answerflag
C8
answeredcoldpack_8850k3728 Jul 2024
7This should be in the site help pages rather than buried in an answer. – n_takahashi 43 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.